Compare Sprott Uranium Miners ETF (URNM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sprott Uranium Miners ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Sprott Uranium Miners ETF trades at $46.35 (market cap $1.87B), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 5.4× Sprott Uranium Miners ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sprott Uranium Miners ETF for 61 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| URNM | XBI | |
|---|---|---|
Market Cap | $1.87B | $10.11B |
Volume | 1,586,926 | 12,903,266 |
Sector | Commodities - Metals/Agriculture | Broad Market / Factor |
52-Week High | $83.99 | $169.55 |
52-Week Low | $46.09 | $104.99 |
Typical Hold Time | 61 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
URNM (Sprott Uranium Miners ETF) trades at $46.43, down 3.01% today amid bearish technical signals. The ETF shows 13 sell signals versus 0 buy signals across moving averages, with oversold RSI readings suggesting potential near-term stabilization. Recent news highlights uranium's strong fundamentals driven by AI power demand and government nuclear investments, though the sector faces volatility from supply-demand imbalances.
Long-term outlook remains positive given nuclear energy's role in AI infrastructure and global decarbonization. Key risks include uranium price volatility and geopolitical supply constraints. Analyst sentiment leans bullish on uranium's structural deficit, with institutional interest growing in pure-play uranium mining exposure.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
